RESTORATIVE PLASTICITY AT CORTICOSTRIATAL EXCITATORY SYNAPSESA project funded by the European Union Seventh Framework ProgrammeFP7/2007-2013 under grant agreement n° 222918
Graph and Illustrations:The Visual Agency
PARKINSON’S DISEASE (PD)is one of the most common
chronic progressive neurodegenerative diseaseshas a prevalence of 1.2 million people in Europe
and an annual cost of 11 billion Euros,
being one of the 12 most costly brain diseases in Europe
Di Luca M, Baker M, Corradetti R, Kettenmann H, Mendlewicz J, Olesen J, Ragan I, Westphal M. Eur J Neurosci. 2011
COST OF DISORDERS OF THE BRAIN IN EUROPE
Estimates in 2004
Estimates in 2010
European Neuropsychopharmacology (2011) 21, 718-779
(1) Referred to as “effective disorders” in 2005, (2) includes only incident cases in 2010, (3) weighted mean from all countries and diagnoses(5) including also persons with zero costs, (6) excluding indirect costs, (7) excluding PTSD.
COST OF DISORDERS OF THE BRAIN IN EUROPE
Estimates in 2004
Estimates in 2010
European Neuropsychopharmacology (2011) 21, 718-779
(1) Referred to as “effective disorders” in 2005, (2) includes only incident cases in 2010, (3) weighted mean from all countries and diagnoses(5) including also persons with zero costs, (6) excluding indirect costs, (7) excluding PTSD.
The cost of brain diseases in Europe has been estimated 798 billion euros
(The economic cost of brain disorders in Europe. Olesen et al, Eur J Neurol. 2012)
WHAT DO WE ASK TO RESEARCH?
How to impact on disease onset and progression,to effectively help those citizens
LEAVING WITH PD
A strong translational character:Understanding the brain functioning at molecular, cellularand system level is essential to unravel pathogenesis of
brain disease
Per visualizzare quest'immagine sono necessari QuickTime™ e undecompressore
.
A spine is moving!A confocal microscopy analysis
Per visualizzare quest'immagine sono necessari QuickTime™ e undecompressore
.
IN VITRO...
PureStriatum
Striatumco-culturedwith cortex
IN VIVO...AAV α-synuclein model of PD: progressive neurodegeneration
Per visualizzare quest'immagine sono necessari QuickTime™ e undecompressore
.
3 NOVELHYPOTHESES TO CURE
METABOTROPIC GLUTAMATE RECEPTOR TYPE 5 (mGluR5) AS A TARGET FOR THE TREATMENT OF L-DOPA-INDUCED DYSKINESIA
Per visualizzare quest'immagine sono necessari QuickTime™ e undecompressore
.
SYNAPTIC LOCALIZATOR OF NR2A SUBUNITIN CHRONIC L-DOPA TREATED ANIMALS MODULATES DYSKINETIC MOTOR BEHAVIOUR
Per visualizzare quest'immagine sono necessari QuickTime™ e undecompressore
.
TAT-2ATAT-2A(-SDV)
Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg - Lys-Met-Pro-Ser-Ile-Glu-Ser-Asp-ValTyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg - Lys-Met-Pro-Ser-Ile-Glu
TAT NR2A C-tail
REBALANCE OF STRIATAL NMDA/AMPA RECEPTOR RATIO UNDERLIES THE REDUCED EMERGENCE OF DYSKINESIA DURING D2-LIKE DOPAMINE AGONIST TREATMENT
Per visualizzare quest'immagine sono necessari QuickTime™ e undecompressore
.
Per visualizzare quest'immagine sono necessari QuickTime™ e undecompressore
.THANK YOU
Graph and Illustrations:The Visual Agency